IBDEI1JQ ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27450,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,27450,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,27450,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,27451,0)
 ;;=253.2^^162^1782^33
 ;;^UTILITY(U,$J,358.3,27451,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27451,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,27451,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,27451,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,27452,0)
 ;;=733.00^^162^1782^43
 ;;^UTILITY(U,$J,358.3,27452,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27452,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,27452,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,27452,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,27453,0)
 ;;=278.00^^162^1782^40
 ;;^UTILITY(U,$J,358.3,27453,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27453,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,27453,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,27453,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,27454,0)
 ;;=278.01^^162^1782^39
 ;;^UTILITY(U,$J,358.3,27454,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27454,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,27454,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,27454,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,27455,0)
 ;;=250.80^^162^1782^4
 ;;^UTILITY(U,$J,358.3,27455,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27455,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,27455,1,5,0)
 ;;=5^DM Type II w/ LE Ulcer
 ;;^UTILITY(U,$J,358.3,27455,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,27456,0)
 ;;=250.00^^162^1782^9
 ;;^UTILITY(U,$J,358.3,27456,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27456,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,27456,1,5,0)
 ;;=5^DM Type II w/o Complications
 ;;^UTILITY(U,$J,358.3,27456,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,27457,0)
 ;;=250.40^^162^1782^5
 ;;^UTILITY(U,$J,358.3,27457,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27457,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,27457,1,5,0)
 ;;=5^DM Type II w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,27457,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,27458,0)
 ;;=250.50^^162^1782^7
 ;;^UTILITY(U,$J,358.3,27458,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27458,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,27458,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,27458,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,27459,0)
 ;;=250.60^^162^1782^6
 ;;^UTILITY(U,$J,358.3,27459,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27459,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,27459,1,5,0)
 ;;=5^DM Type II w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,27459,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,27460,0)
 ;;=250.70^^162^1782^8
 ;;^UTILITY(U,$J,358.3,27460,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27460,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,27460,1,5,0)
 ;;=5^DM Type II w/ Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,27460,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,27461,0)
 ;;=250.01^^162^1782^3
 ;;^UTILITY(U,$J,358.3,27461,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27461,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,27461,1,5,0)
 ;;=5^DM Type I w/o Complications
 ;;^UTILITY(U,$J,358.3,27461,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,27462,0)
 ;;=272.0^^162^1782^22
 ;;^UTILITY(U,$J,358.3,27462,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27462,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,27462,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,27462,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,27463,0)
 ;;=272.1^^162^1782^27
 ;;^UTILITY(U,$J,358.3,27463,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27463,1,4,0)
 ;;=4^272.1
 ;;
 ;;$END ROU IBDEI1JQ
